Equities analysts expect FibroGen, Inc. (NASDAQ:FGEN – Get Rating) to report earnings of ($0.82) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for FibroGen’s earnings. The lowest EPS estimate is ($1.01) and the highest is ($0.39). FibroGen posted earnings per share of ($0.78) during the same quarter last year, which would suggest a negative year over year growth rate of 5.1%. The company is expected to issue its next earnings results on Monday, January 1st.
On average, analysts expect that FibroGen will report full-year earnings of ($3.17) per share for the current year, with EPS estimates ranging from ($4.18) to ($1.44). For the next year, analysts expect that the business will post earnings of ($1.84) per share, with EPS estimates ranging from ($3.39) to ($0.76). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow FibroGen.
FibroGen (NASDAQ:FGEN – Get Rating) last announced its earnings results on Monday, February 28th. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.77). FibroGen had a negative return on equity of 93.23% and a negative net margin of 123.25%. The company had revenue of $16.54 million during the quarter, compared to the consensus estimate of $47.65 million. During the same period in the prior year, the firm posted ($0.64) earnings per share. The company’s revenue was down 74.5% on a year-over-year basis.
FGEN stock opened at $12.51 on Thursday. The stock has a market capitalization of $1.16 billion, a PE ratio of -3.98 and a beta of 0.79. The company has a 50 day moving average price of $13.59 and a 200 day moving average price of $13.10. FibroGen has a fifty-two week low of $9.88 and a fifty-two week high of $30.12.
Institutional investors have recently made changes to their positions in the business. National Bank of Canada FI bought a new position in shares of FibroGen during the 4th quarter valued at about $33,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in shares of FibroGen in the first quarter valued at approximately $59,000. Point72 Hong Kong Ltd bought a new stake in shares of FibroGen during the third quarter worth $65,000. Royal Bank of Canada raised its holdings in shares of FibroGen by 20.6% during the third quarter. Royal Bank of Canada now owns 7,451 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 1,271 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in FibroGen in the 3rd quarter valued at $111,000. Institutional investors own 75.75% of the company’s stock.
About FibroGen (Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Insiders Are Selling Palo Alto Networks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.